1. Home
  2. BLDE vs SLN Comparison

BLDE vs SLN Comparison

Compare BLDE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLDE
  • SLN
  • Stock Information
  • Founded
  • BLDE 2014
  • SLN 1994
  • Country
  • BLDE United States
  • SLN United Kingdom
  • Employees
  • BLDE N/A
  • SLN N/A
  • Industry
  • BLDE Aerospace
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLDE Consumer Discretionary
  • SLN Health Care
  • Exchange
  • BLDE Nasdaq
  • SLN Nasdaq
  • Market Cap
  • BLDE 285.2M
  • SLN 273.9M
  • IPO Year
  • BLDE N/A
  • SLN N/A
  • Fundamental
  • Price
  • BLDE $4.27
  • SLN $6.11
  • Analyst Decision
  • BLDE Strong Buy
  • SLN Buy
  • Analyst Count
  • BLDE 2
  • SLN 5
  • Target Price
  • BLDE $6.25
  • SLN $32.60
  • AVG Volume (30 Days)
  • BLDE 739.9K
  • SLN 105.4K
  • Earning Date
  • BLDE 08-06-2025
  • SLN 08-14-2025
  • Dividend Yield
  • BLDE N/A
  • SLN N/A
  • EPS Growth
  • BLDE N/A
  • SLN N/A
  • EPS
  • BLDE N/A
  • SLN N/A
  • Revenue
  • BLDE $251,485,000.00
  • SLN $27,701,000.00
  • Revenue This Year
  • BLDE $5.79
  • SLN N/A
  • Revenue Next Year
  • BLDE $8.35
  • SLN N/A
  • P/E Ratio
  • BLDE N/A
  • SLN N/A
  • Revenue Growth
  • BLDE 8.67
  • SLN N/A
  • 52 Week Low
  • BLDE $2.35
  • SLN $1.97
  • 52 Week High
  • BLDE $5.17
  • SLN $22.47
  • Technical
  • Relative Strength Index (RSI)
  • BLDE 61.55
  • SLN 55.70
  • Support Level
  • BLDE $4.02
  • SLN $6.10
  • Resistance Level
  • BLDE $4.65
  • SLN $6.67
  • Average True Range (ATR)
  • BLDE 0.19
  • SLN 0.39
  • MACD
  • BLDE 0.01
  • SLN -0.02
  • Stochastic Oscillator
  • BLDE 60.99
  • SLN 59.70

About BLDE Blade Air Mobility Inc.

Blade Air Mobility Inc is a technology-powered air mobility platform that provides air transportation and logistics for hospitals and is a transporter of human organs for transplant, and for passengers, with helicopter and fixed-wing services predominantly in the Northeast United States, Southern Europe and Western Canada. The company's operating segments are; Passenger, and Medical. Majority of the revenue for the company is generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services. It also offers additional services including donor logistics coordination and support in evaluating potential donor organs. A substantial portion of the company's revenue is generated from the United States.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: